Education
About Us
Working with TipRanks
Follow Us
Viracta Therapeutics (VIRX)
OTHER OTC:VIRX
Total Valuation
Viracta Therapeutics has a market cap or net worth of $695.52K. The enterprise value is $43.56M.
Market Cap$695.52K
Enterprise Value$43.56M
Share Statistics
Viracta Therapeutics has 39,744,220 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding39,744,220
Owned by Insiders2.48%
Owned by Institutions0.27%
Financial Efficiency
Viracta Therapeutics’s return on equity (ROE) is -2.79 and return on invested capital (ROIC) is -115.54%.
Return on Equity (ROE)-2.79
Return on Assets (ROA)-0.90
Return on Invested Capital (ROIC)-115.54%
Return on Capital Employed (ROCE)-2.77
Revenue Per Employee0.00
Profits Per Employee-1.96M
Employee Count26
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Viracta Therapeutics is -0.43. Viracta Therapeutics’s PEG ratio is 0.01.
PE Ratio-0.43
PS Ratio0.00
PB Ratio0.90
Price to Fair Value1.20
Price to FCF-1.55
Price to Operating Cash Flow-1.56
PEG Ratio0.01
Income Statement
In the last 12 months, Viracta Therapeutics had revenue of 0.00 and earned -51.06M in profits. Earnings per share was -1.32.
Revenue0.00
Gross Profit-492.00K
Operating Income-50.69M
Pretax Income-51.06M
Net Income-51.06M
EBITDA-46.86M
Earnings Per Share (EPS)-1.32
Cash Flow
In the last 12 months, operating cash flow was -34.80M and capital expenditures 0.00, giving a free cash flow of -34.80M billion.
Operating Cash Flow-34.80M
Free Cash Flow-34.80M
Free Cash Flow per Share-0.88
Dividends & Yields
Viracta Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta-0.62
52-Week Price Change-96.92%
50-Day Moving Average0.02
200-Day Moving Average0.12
Relative Strength Index (RSI)43.77
Average Volume (3m)98.80K
Important Dates
Viracta Therapeutics upcoming earnings date is Aug 6, 2025, TBA Not Confirmed.
Last Earnings DateMay 7, 2025
Next Earnings DateAug 6, 2025
Ex-Dividend Date―
Financial Position
Viracta Therapeutics as a current ratio of 1.43, with Debt / Equity ratio of 41.17%
Current Ratio1.43
Quick Ratio1.43
Debt to Market Cap1.15
Net Debt to EBITDA-0.28
Interest Coverage Ratio-13.69
Taxes
In the past 12 months, Viracta Therapeutics has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Viracta Therapeutics EV to EBITDA ratio is -0.75, with an EV/FCF ratio of -0.88.
EV to Sales0.00
EV to EBITDA-0.75
EV to Free Cash Flow-0.88
EV to Operating Cash Flow-0.88
Balance Sheet
Viracta Therapeutics has $21.13M in cash and marketable securities with $16.91M in debt, giving a net cash position of -$4.22M billion.
Cash & Marketable Securities$21.13M
Total Debt$16.91M
Net Cash-$4.22M
Net Cash Per Share-$0.11
Tangible Book Value Per Share$0.47
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Viracta Therapeutics is $0.25, which is 11.43% higher than the current price. The consensus rating is Hold
Price Target$0.25
Price Target Upside1150.00% Upside
Analyst ConsensusHold
Analyst Count0
Revenue Growth Forecast―
EPS Growth Forecast10.59%